[
    [
        {
            "time": "2021-04",
            "original_text": "医药行业2021年4月投资月报：把握一季报最佳反弹窗口期 加配低估值且高增长标的",
            "features": {
                "keywords": [
                    "医药",
                    "一季报",
                    "反弹",
                    "低估值",
                    "高增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2021年4月投资月报：把握一季报最佳反弹窗口期 加配低估值且高增长标的",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-W16",
            "original_text": "医药行业周报：当前是反弹最佳窗口期 加配低估值高增长标的",
            "features": {
                "keywords": [
                    "医药",
                    "反弹",
                    "低估值",
                    "高增长"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：当前是反弹最佳窗口期 加配低估值高增长标的",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-W16",
            "original_text": "医药行业每周医览药闻：从2020年财报看国内创新药行业发展",
            "features": {
                "keywords": [
                    "医药",
                    "财报",
                    "创新药",
                    "发展"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业每周医览药闻：从2020年财报看国内创新药行业发展",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-H2",
            "original_text": "群益证券(香港) - 泰格医药：20H2业绩恢复明显，并且在手订单充足，看好公司长远发展【公司研究】",
            "features": {
                "keywords": [
                    "泰格医药",
                    "业绩",
                    "订单",
                    "长远发展"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "群益证券(香港) - 泰格医药：20H2业绩恢复明显，并且在手订单充足，看好公司长远发展【公司研究】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021",
            "original_text": "宝盈基金明星医药经理“闪电”离职，爆款候选人年内业绩表现不佳 基金经理离任",
            "features": {
                "keywords": [
                    "宝盈基金",
                    "医药经理",
                    "离职",
                    "业绩不佳"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "宝盈基金明星医药经理“闪电”离职，爆款候选人年内业绩表现不佳 基金经理离任",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-W16",
            "original_text": "医药行业周报：核心资产景气回归 关注第二批耗材集采进程",
            "features": {
                "keywords": [
                    "医药",
                    "核心资产",
                    "景气回归",
                    "耗材集采"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：核心资产景气回归 关注第二批耗材集采进程",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-04",
            "original_text": "2021年医药行业4月策略报告：Q1业绩高成长是股价核心催化剂",
            "features": {
                "keywords": [
                    "医药",
                    "Q1业绩",
                    "高成长",
                    "股价",
                    "催化剂"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2021年医药行业4月策略报告：Q1业绩高成长是股价核心催化剂",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021",
            "original_text": "CRO板块闪崩，龙头药明康德、康龙化成双双跌超4%",
            "features": {
                "keywords": [
                    "CRO",
                    "闪崩",
                    "药明康德",
                    "康龙化成"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "CRO板块闪崩，龙头药明康德、康龙化成双双跌超4%",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]